China National Medicines's Total Assets for the quarter that ended in Mar. 2024 was ¥32,919 Mil.
Warning Sign:
If a company builds assets at 5.2% a year, faster than its revenue growth rate of 4.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, China National Medicines's average Total Assets Growth Rate was 7.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 4.80% per year.
During the past 5 years, the average Total Assets Growth Rate was 5.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 18.90% per year.
During the past 13 years, China National Medicines's highest 3-Year average Total Assets Growth Rate was 48.30%. The lowest was -1.40%. And the median was 17.20%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
China National Medicines's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Medicines (SHSE:600511) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
China National Medicines's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
China National Medicines Total Assets Related Terms
Thank you for viewing the detailed overview of China National Medicines's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
China National Medicines (SHSE:600511) Business Description
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company is also engaged in proprietary Chinese medicines, Chinese medicine decoction pieces, Chinese medicinal materials, chemical preparations, chemical raw materials, antibiotics, and biochemical drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:600511 has been successfully added to your 